Citations

Clear

1819 citation(s) found for "Israel, E".

De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel
Sparrow, Miles , Melmed, Gil , Devlin, Shane , Raffals, Laura E. , Loftus, Edward V. , Rubin, David T. , Bressler, Brian , Cheifetz, Adam S. , Jones, Jennifer , Velayos, Fernando, Loftus, Edward V , Melmed, Gil Y , Rubin, David T , Kozuch, Patricia L. , Spiegel, Brennan , Baidoo, Leonard , Irving, Peter Miles , Kaplan, Gilaad G. , Siegel, Corey A

Mayo Clinic

GastroHep | April 30, 2019 | Volume: 1 | Issue: 3 | Pages: 108-117

10.1002/ygh2.337 Get It

Volumetric laser endomicroscopy and its application to Barrett's esophagus: results from a 1,000 patient registry
Smith, Michael S. , Konda, Vani J. , Gordon, Stuart R. , DeMeester, Steven R. , Joshi, Vivek , Ganguly, Eric K. , Mashimo, Hiroshi , Jobe, Blair A. , McKinley, Matthew , Wallace, Michael B. , Thakkar, Shyam , Schnoll‐Sussman, Felice , Sharaiha, Reem Z. , Tarnasky, P, Wolfsen, Herbert C. , Hawes, Robert H. , Lipham, John C. , Khara, Harshit S. , Navaneethan, U, Kedia, Prashant , Hasan, Muhammad K. , Sethi, Amrita , Samarasena, Jason , Siddiqui, Uzma D. , Gress, Frank G., Rodríguez, Reynaldo , Lee, C, Gonda, Tamas A. , Waxman, Irving , Hyder, S., Poneros, John M., Sharzehi, Kaveh , Palma, Jack A. Di, Sejpal, Divyesh V., Hagen, J. A., Rothstein, Richard, Sawhney, Mandeep , Malik, Zubair , Chang, Kenneth J. , Fichera, Alessandro , Gaidhane, Monica , Wallace, Michael B , Cash, Brooks D. , Trindade, Arvind J. , Diehl, David L. , Singh, Satish K. , Komatsu, Y, Kahaleh, Michel , Pleskow, Douglas K. , Hyder, S, Oh, Daniel S. , Berzin, Tyler M.

Mayo Clinic

Diseases of the Esophagus | April 30, 2019 | Volume: 32 | Issue: 9 | Pages: No page available

10.1093/dote/doz029 | PMID 31037293 Get It

SUMMARY Volumetric laser endomicroscopy (VLE) uses optical coherence tomography (OCT) for real-time, microscopic cross-sectional imaging. A US-based multi-center registry was constructed to prospectively collect data on patients undergoing upper endoscopy during which a VLE scan was performed. The objective of this registry was to determine usage patterns of VLE in clinical practice and to estimate quantitative and qualitative performance metrics as they are applied to Barrett's esophagus (BE) management. All procedures utilized the NvisionVLE Imaging System (NinePoint Medical, Bedford, MA) which was used by investigators to identify the tissue types present, along with focal areas of concern. Following the VLE procedure, investigators were asked to answer six key questions regarding how VLE impacted each case. Statistical analyses including neoplasia diagnostic yield improvement using VLE was performed. One thousand patients were enrolled across 18 US trial sites from August 2014 through April 2016. In patients with previously diagnosed or suspected BE (894/1000), investigators used VLE and identified areas of concern not seen on white light endoscopy (WLE) in 59% of the procedures. VLE imaging also guided tissue acquisition and treatment in 71% and 54% of procedures, respectively. VLE as an adjunct modality improved the neoplasia diagnostic yield by 55% beyond the standard of care practice. In patients with no prior history of therapy, and without visual findings from other technologies, VLE-guided tissue acquisition increased neoplasia detection over random biopsies by 700%. Registry investigators reported that VLE improved the BE management process when used as an adjunct tissue acquisition and treatment guidance tool. The ability of VLE to image large segments of the esophagus with microscopic cross-sectional detail may provide additional benefits including higher yield biopsies and more efficient tissue acquisition. Clinicaltrials.gov NCT02215291
Sex Disparities in First Medical Contact of Patients with Suspected Acute Coronary Syndrome Using Telemedicine Technology
Maor, Elad , Abend, Yitzhak, Ganem, Diab, Kusniec, Fabio, Grosman‐Rimon, Liza , Carasso, Shemy , Amir, Offer, Maor, Elad , Elbaz‐Greener, Gabby , Lerman, Amir

Mayo Clinic

Telemedicine and e-Health | April 26, 2019 | Volume: 26 | Issue: 4 | Pages: 411-418

10.1089/tmj.2019.0036 | PMID 31025897 Get It

Background: Reducing door-to-balloon time may not reduce mortality, but reducing the time from symptom onset to first medical contact (FMC) may alone improve patient outcomes. The purpose of this study was to focus on analyzing sex differences in FMC call delay and its trend over the decades in patients with suspected acute coronary syndrome (ACS). Methods: Large private telemedicine data in patients with suspected ACS were used to investigate time delay in contacting a telemedicine call center. We identified 24,592 calls to a primary call center of patients with anginal symptoms and first electrocardiogram (ECG), using mobile 12-lead ECG devices. For the purpose of the current analysis, we included the first call of 14,420 patients for whom demographic, clinical ECG data were available. Results: First mobile ECG changes included suspected S-T Segment (ST) elevation in 2,220 (16%) cases, ST depression in 3,143 (22%) cases, or both in 685 (5%) patients. There were 6,721 (47%) calls to the center within less than 1 h of symptom onset. Chest pain, dyspnea, heart rate, male sex, absence of diabetes mellitus, early time period of the study, and ischemic ST segment changes on the first ECG were all independently associated with the increased likelihood of contacting the center within less than 1 h of symptom onset to FMC ( p < 0.01 for all). Conclusions: Both chest pain and ischemic ECG changes were sex dependent for early medical contact, as such factors were significant among men ( p = 0.001 and p = 0.024, respectively), but not among women ( p = 0.024). The later time period of the study was associated with a shorter time delay among women more than that of men ( p = 0.014). Women with prehospital chest pain or ischemic ST segment changes tend to seek medical help later than men. Temporal trends show attenuation of this sex disparity, with more women presenting earlier in the last decade.
US State Regulation of Decisions for Pregnant Women Without Decisional Capacity
DeMartino, Erin S. , Sperry, Beau P. , Doyle, Cavan K. , Chor, Julie , Kramer, Daniel B. , Mueller, Paul S. , Dudzinski, David M.

Mayo Clinic

JAMA | April 23, 2019 | Volume: 321 | Issue: 16 | Pages: 1629

10.1001/jama.2019.2587 | PMID 31012920 Get It

Treatment-related amenorrhea among young women one year following diagnosis of early-stage breast cancer.
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Come, Steven E. , Schapira, Lidia , Tamimi, Rulla M. , Bober, Sharon L. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9523-9523

10.1200/jco.2015.33.15_suppl.9523 Get It

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma
DiNorcia, Joseph , Haydel, Brandy , Tabrizian, Parissa , Ruiz, Richard , Klintmalm, Göran B. , Senguttuvan, Srinath, Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nguyen, Mindie H. , Melcher, Marc L. , Tevar, Amit D. , Humar, Abhinav , Mobley, Constance M. , Ghobrial, R. Mark , Nydam, Trevor L. , Amundsen, Beth, Markmann, James F. , Berumen, Jennifer , Hemming, Alan W. , Langnas, Alan N. , Carney, Carol A., Sudan, Debra L. , Hong, Johnny C. , Kim, Joohyun , Zimmerman, Michael A. , Rana, Abbas , Kueht, Michael , Jones, Christopher M. , Fishbein, Thomas , Markovic, Daniela , Busuttil, Ronald W. , Taner, C. Burcin , Lee, David D , Melcher, Marc L , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Florman, Sander , Hoteit, Maarouf , Levine, Matthew H , Agopian, Vatche G.

Mayo Clinic

Annals of Surgery | March 22, 2019 | Volume: 271 | Issue: 4 | Pages: 616-624

10.1097/sla.0000000000003253 | PMID 30870180 Get It

Objective: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT). Background: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study. Methods: Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predictors of cPR were identified using logistic regression. Results: Of 3439 patients, 802 (23%) had cPR on explant. Compared with patients without cPR, cPR patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil–lymphocyte ratios (NLR); were more likely to have tumors within Milan criteria and fewer LRT treatments; and had significantly lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%; P < 0.001). Multivariable predictors of cPR included age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT treatments (C-statistic 0.67). Conclusions: For LT recipients with HCC receiving pretransplant LRT, achieving cPR portends significantly lower posttransplant recurrence and superior survival. Factors predicting cPR are identified, which may help prioritize patients and guide LRT strategies to optimize posttransplant cancer outcomes.
Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis
Kaewput, Wisit , Thamcharoen, Natanong , Cheungpasitporn, Wisit , Watthanasuntorn, Kanramon , Lertjitbanjong, Ploypin , Sharma, Konika , Salim, Sohail Abdul , Ungprasert, Patompong , Kröner, Paul T. , Aeddula, Narothama Reddy , Mao, Michael A. , Kaewput, Wisit , Kröner, Paul T , Aeddula, Narothama Reddy , Mao, Michael A , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

Journal of Clinical Medicine | March 18, 2019 | Volume: 8 | Issue: 3 | Pages: 372

10.3390/jcm8030372 | PMID 30884912 Get It

Background: The study’s aim was to summarize the incidence and impacts of post-liver transplant (LTx) acute kidney injury (AKI) on outcomes after LTx. Methods: A literature search was performed using the MEDLINE, EMBASE and Cochrane Databases from inception until December 2018 to identify studies assessing the incidence of AKI (using a standard AKI definition) in adult patients undergoing LTx. Effect estimates from the individual studies were derived and consolidated utilizing random-effect, the generic inverse variance approach of DerSimonian and Laird. The protocol for this systematic review is registered with PROSPERO (no. CRD42018100664). Results: Thirty-eight cohort studies, with a total of 13,422 LTx patients, were enrolled. Overall, the pooled estimated incidence rates of post-LTx AKI and severe AKI requiring renal replacement therapy (RRT) were 40.7% (95% CI: 35.4%–46.2%) and 7.7% (95% CI: 5.1%–11.4%), respectively. Meta-regression showed that the year of study did not significantly affect the incidence of post-LTx AKI (p = 0.81). The pooled estimated in-hospital or 30-day mortality, and 1-year mortality rates of patients with post-LTx AKI were 16.5% (95% CI: 10.8%–24.3%) and 31.1% (95% CI: 22.4%–41.5%), respectively. Post-LTx AKI and severe AKI requiring RRT were associated with significantly higher mortality with pooled ORs of 2.96 (95% CI: 2.32–3.77) and 8.15 (95%CI: 4.52–14.69), respectively. Compared to those without post-LTx AKI, recipients with post-LTx AKI had significantly increased risk of liver graft failure and chronic kidney disease with pooled ORs of 3.76 (95% CI: 1.56–9.03) and 2.35 (95% CI: 1.53–3.61), respectively. Conclusion: The overall estimated incidence rates of post-LTx AKI and severe AKI requiring RRT are 40.8% and 7.0%, respectively. There are significant associations of post-LTx AKI with increased mortality and graft failure after transplantation. Furthermore, the incidence of post-LTx AKI has remained stable over the ten years of the study.
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Gelman, Rebecca , Anders, Carey K. , Melisko, Michelle , Parsons, Heather A. , Cropp, Anne B., Silvestri, Kelly M., Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisín M. , Poznak, Catherine Van , Blackwell, Kimberly , Puhalla, Shannon L. , Jankowitz, Rachel C. , Ibrahim, Nuhad K. , Moynihan, Timothy J. , O’Sullivan, Ciara C. , Nangia, Julie R. , Pohlmann, Paula R. , Burns, Robyn, Rimawi, Mothaffar F. , Krop, Ian E. , O'Sullivan, Ciara C, Rimawi, Mothaffar , Freedman, Rachel A. , Moy, Beverly , Smith, Karen L. , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1081-1089

10.1200/jco.18.01511 | PMID 30860945 Get It

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.